In this article

本文中

LLY

LLY

Follow your favorite stocks

关注你喜爱的股票

CREATE FREE ACCOUNT

创建免费账户

A drone view shows the Eli Lilly logo on the company’s office in San Diego, California, Nov. 21, 2025.

无人机视角显示了2025年11月21日加利福尼亚州圣地亚哥的礼来公司办公室上的公司标志。

Mike Blake | Reuters

迈克·布莱克 | 路透社

BEIJING — U.S. pharmaceutical giant

北京——美国制药巨头

Eli Lilly

礼来公司

has reached a $2.75 billion deal to bring drugs developed using artificial intelligence by Hong Kong-based Insilico Medicine to the global market.

已达成了 27.5 亿美元的协议，将香港 Insilico Medicine 开发的利用人工智能开发的药物推向全球市场。

The agreement will give Insilico $115 million up front, with the remainder subject to regulatory and commercial milestones, along with royalties on future sales, according to the companies' announcement Monday.

根据公司周一的公告，该协议将使英矽智能获得1.15亿美元的预付款，剩余款项取决于监管和商业里程碑，以及未来销售额的特许权使用费。

Insilico has developed at least 28 drugs using generative AI tools, with nearly half already at a clinical stage, Alex Zhavoronkov, founder and CEO of Insilico, told CNBC. The company went public in Hong Kong in December. Its shares are up more than 50% year-to-date.

英矽智能创始人兼首席执行官亚历克斯·扎沃隆科夫告诉CNBC，该公司已经利用生成式人工智能工具开发了至少28种药物，其中近一半已经在临床阶段。该公司于去年12月在香港上市，其股价今年以来上涨超过50%。

'In many ways, Lilly is better than us in some areas of AI,' Zhavoronkov said, noting the U.S. pharma giant has 'one person' who has brought biology, chemistry and automation under one roof. He added that as part of the deal, Insilico will join

“在许多方面，礼来在某些人工智能领域比我们更优秀，”Zhavoronkov说道，并指出这家美国制药巨头有“一个人”将生物学、化学和自动化整合到了一起。他补充说，作为协议的一部分，Insilico将加入。

Lilly's Gateway Labs

莉莉的门户实验室

community for biotech development.

生物技术发展社区。

The two companies have worked together since signing an

两家公司自签署协议以来一直合作。

AI-based software licensing agreement in 2023

基于人工智能的软件许可协议 2023

.

。

'This collaboration allows us to explore novel mechanisms and accelerate the identification of promising therapeutic

“这次合作使我们能够探索新机制并加速识别有前景的治疗方法

c

c

andidates across multiple disease areas,' Andrew Adams, group vice president of Molecule Discovery at Lilly, said in a statement. He called Insilico's AI-enabled discovery 'a powerful complement' to Lilly's clinical development.

“我们很高兴能与英矽智能合作，探索多个疾病领域的候选药物，”礼来公司分子发现集团副总裁安德鲁·亚当斯在一份声明中表示。他称英矽智能的AI驱动发现是礼来临床开发的“有力补充”。

Eli Lilly CEO David A. Ricks attended a

礼来公司首席执行官大卫·A·里克斯出席了

high-level forum in Beijing

北京高级别论坛

earlier this month, just weeks after the company announced plans to

本月初，就在该公司宣布计划的几周后

invest $3 billion in China

在中国投资30亿美元

over the next decade. The company reported that slightly less than

在接下来的十年中。公司报告称略低于

3% of its revenue

收入的3%

came from China last year.

去年从中国来。

Weekly analysis and insights from Asia's largest economy in your inbox

每周分析和来自亚洲最大经济体的洞察，发送到您的邮箱

Subscribe now

订阅现在

Insilico develops its AI outside of China, in Canada and the Middle East, but conducts early preclinical drug development in China based on that AI research, Zhavoronkov said. In addition to reducing research time, he said AI can synthesize molecules more quickly than those discovered using more traditional methods..

Zhavoronkov 表示，Insilico 在中国以外的加拿大和中东地区开发其人工智能技术，但会基于该人工智能研究在中国进行早期临床前药物开发。他表示，除了缩短研究时间外，人工智能还能够比传统方法更快地合成分子。

Choose CNBC as your preferred source on Google and never miss a moment from the most trusted name in business news.

将CNBC设置为Google上的首选来源，不错过商业新闻最值得信赖的名字的任何时刻。